The adaptive immune response, and in particular T cells have been shown to be important in the genesis of hypertension. In the present study, we sought to determine how angiotensin II, the NADPH oxidase and reactive oxygen species interplay with T cells to modulate their activation and ultimately hypertension. We determined that T cells express angiotensinogen, the angiotensin I-converting enzyme and renin and produce physiological levels of angiotensin II.
INTRODUCTION
The renin-angiotensin system (RAS) is a prominent mediator of hypertension and a key target in the treatment of this disease. Angiotensin II has myriad effects on the cardiovascular system. In many tissues, angiotensin II activates the NADPH oxidase to produce reactive oxygen species (ROS) (16) . In the cardiovascular system, this effect of angiotensin II has been linked to induction of cardiac hypertrophy, inflammation, lipid oxidation, endothelial dysfunction and ultimately increased blood pressure (4) .
We have recently demonstrated that the T cell plays an important role in the development of hypertension (18) . Angiotensin II increases T cell activation, production of pro-inflammatory cytokines, and infiltration into perivascular fat. At this site, the T cell can produce cytokines and release other mediators that affect the smooth muscle cells and endothelium of the adjacent vessel. In this prior study, we demonstrated that the TNFα antagonist, etanercept prevented angiotensin II-induced increase in blood pressure and vascular superoxide production, suggesting an important role of this cytokine in hypertension.
In addition to the classical components required for T cell function, T cells express other proteins not typically associated with immune responses, suggesting alternate physiological and pathological roles for the T cell. For example, T cells contain components of the RAS such as the angiotensin I-converting enzyme (ACE) (6) , renin, the renin receptor, and angiotensinogen (Agt) (24) . This suggests that T cells may be able to produce angiotensin II and thus contribute to the local RAS in tissues, however T cell production of angiotensin II has not yet been demonstrated.
Because of the established contributions of angiotensin II, NADPH oxidase and reactive oxygen species (ROS) to hypertension, we sought to determine if these mediators were involved in modulation of T cell function. Our findings indicate that T cells have a functional RAS, that they produce angiotensin II, and that the majority of AT 1 receptors are expressed within the T cell, suggesting an intracrine RAS. Our results demonstrate that angiotensin II has direct actions on T cell function, including activation, expression tissue homing markers, and production of TNFα. We further identified a role of the T cell NADPH oxidase and superoxide production in this angiotensin II-dependent modulation of T cell function.
METHODS

Animals:
Mice were maintained in the Emory Animal Facility under standard conditions (12:12 h dark:light cycle, 20°C room temperature), and were given Purina Rodent Chow 5001 diet and water ad libitum. The Institutional Animal Care and Use Committee at Emory University approved all experimental protocols. C57Bl/6 and RAG1 -/-mice were obtained from Jackson
Laboratories. The p47 phox-/-mice and their appropriate controls were obtained from Taconic.
AT 2 R -/-mice were bred from animals provided by Dr. Tadashi Inagami (Vanderbilt University).
All mice were on a C57Bl/6 background. Angiotensin II (490 ng/min/kg) was infused and blood pressure measured non-invasively as described previously (44). For adoptive transfer, mice were anesthetized with xylazine/ketamine and cells were injected via tail vein. Angiotensin II infusion and blood pressure monitoring was begun 3 weeks after adoptive transfer.
T cell isolation and culture: CD4+, CD8+, or all T cells were isolated from peripheral blood mononuclear cells (PBMC) and spleens as previously described (18) . Briefly, spleens were removed and disrupted using forceps to release a single cell suspension that was passed through a 70 μm sterile strainer. Total blood leukocytes were isolated from whole heparinized blood, following osmotic lysis of excess red blood cells. Cells were centrifuged (800 X g) and washed twice with PBS. For purified T cell separation, splenocytes or PBMC were isolated from donor mice and were purified using auto-MACS and either CD4+, CD8+, or Pan T cell isolation kits (Miltenyi Biotech, CA). Cell purity was confirmed by FACS analysis to be ≥ 99% by staining a fraction of the isolated T cells with a fluorescent anti-CD3 antibody. T cells were cultured as previously described (18) . Briefly, 2x10 5 cells in 100 μl media were seeded on 96-well plates coated with anti-CD3 antibodies (BD Biosciences), with or without additional treatments, and cultured for various times as indicated for each experiment.
Quantitative real time and standard PCR: RNA was extracted from either T cells or indicated tissues using Trizol (Invitrogen), and purified using procedure with the Qiagen RNeasy
Kit. Following purification, 1 μg was reverse-transcribed using random hexamers and Superscript III (Invitrogen). The resulting cDNA was purified with the PCR Purification Kit (Qiagen). Quantitative expression of each gene of interest was determined using real-time PCR fluorescent probes and primers, which are proprietary products from Applied Biosystems. Each reaction was performed in a total volume of 20 μl, which included 2 μl cDNA, 1 μl TaqMan primers and probes, 7 μl nuclease-free water, and 10 μl TaqMan Gene Expression Master Mix.
Samples were run in triplicate, along with negative water controls. Standard curves for these assays were generated using DNA targets amplified from mouse kidney cDNA using standard PCR primers (Sigma-Genosys) that flank the Taqman Assay Location, and PuReTaq Ready-toGo PCR beads (GE Healthcare). For expression of AT 2 receptors, standard PCR techniques were employed using the following primers designed against the murine sequence for the receptor (Accession number NM_007429): forward 5'-AGAAGGAATCCCTGGCAAGC; reverse 5'-CAAACCAATGGCTAGGCTG. This primer set amplified a target 756 base pairs in length which was isolated using 2 % agarose and visualized using Quantity One software and a Gel-Doc system (both Bio-Rad). nm. The pg/ml value for each sample was calculated by using the A 405corr readings in the linear formula obtained from the standard curve. Cytokine production of T cells were measured using the Cytometric Bead Array (BD Biosciences, San Jose, CA) as previously described (18) .
Briefly, T cells were cultured 48 hours, and the media samples were collected for analysis of the amount of secreted TNF-α, IFN-γ, IL-2, IL-4, and IL-5.
Measurement of superoxide using ESR:
For detection of O 2 ·-the spin probe 1-hydroxy-4-methoxy-2,2,6,6-tetramethylpiperidine (TMH) was used as previously described (43) . T cells The dissolved spin probe was continuously bubbled with argon gas prior to use. ESR spectra were recorded using a Bruker EMX spectrometer using the following settings; field sweep, 80 G; microwave frequency, 9.39 GHz; microwave power, 2 mW; modulation amplitude, 5 G; conversion time, 327.68 ms; time constant, 5242.88 ms; 512 points resolution; and receiver gain, 1x10 4 .
AT 2 R -/-Adoptive transfer, angiotensin II infusion, and measurement of blood pressure:
RAG-1 -/-mice underwent adoptive transfer of 10 7 T cells from either C57Bl/6 or AT 2 -/-mice via tail vein injection as previously described (18) . After allowing three weeks for T cell engraftment, subcutaneous osmotic pumps were then implanted for administration of 490 ng/min/kg angiotensin II, after which T cells from spleens were harvested and stained for T cells markers to verify reconstitution of the T cell population using flow cytometry.
Blood pressure was measured using the tail cuff approach with a device specifically designed for mice (Hatteras Instruments). All tail-cuff measurements were acquired between 8 and 10 AM each day. Animals were accustomed to the device for 5 days before data was acquired. Baseline were too low to be detected. In the absence of anti-CD3, angiotensin II had no stimulatory effect, in keeping with the concept that this hormone acts as a co-stimulatory molecule for T cell activation (30).
In contrast to the modest effect of exogenous angiotensin II on TNFα production from spleenderived T cells, we found that addition of angiotensin II to blood-derived T cells in culture had Moreover, T cell production of angiotensin II was completely prevented by perindopril, confirming specificity of this assay. Among blood-derived T cells, the CD4+ subset produced slightly more angiotensin II than CD8+ cells. Interestingly, T cells from the spleen produced significantly less angiotensin II as compared to circulating T cells. Of interest, when we added 100 nMole/L of exogenous angiotensin II to cultured T cells, the amount of angiotensin II that was detected after 48 hours in culture was 30 pg/ml. This is markedly less than the calculated amount that should have been present given the amount added and volume of the culture medium (1μg/ml), indicating that there is likely marked degradation of angiotensin II in the culture.
It has been previously reported that T cells produce and possess all components of the reninangiotensin system. Using real-time polymerase chain reactions, we were able to confirm that T cells express modest quantities of the angiotensin I-converting enzyme, equivalent to that observed in the kidney for angiotensinogen and in the liver for the ACE (Figure 3b ). T cells also expressed small amounts of renin mRNA, which was much less than that of the kidney, but greater than that found in the liver or lung (figure 3c). T cells also produced angiotensinogen, which again was less than that produced by the liver but greater than that produced by the lung and equivalent to that produced by the kidney (figure 3d).
Angiotensin receptors in T cells:
We also found that T cells express both AT 1a and AT 1b receptors using real-time PCR (Figure 4a ). While we were unable to detect the AT 2 receptor using this approach, conventional PCR techniques identified mRNA for this receptor (Figure 4b ).
We further examined the presence of AT 1 and AT 2 receptors using fluorescent cell sorting.
Conventional surface staining resulted in barely detectable signals (~0.06% expression of AT 1 R, 0.03% for isotype control, figure 4c ). In contrast, intracellular staining revealed that within the CD4+ population of PBMCs, 5% of cells express the AT 1a receptor, while 3.5% the CD8+ population expressed this receptor (Figure 4d ). The amount of AT 2 receptor detected by FACS analysis using either surface or intracellular staining was minimal, and barely above the staining of the isotype control. In additional control experiments, we found that AT 1 R -/-T cells had no intracellular staining for AT 1 receptors (data not shown).
Role of angiotensin II receptor activation on T cell production of TNFα: To gain further insight into the role of the AT 1 receptor in T cell function, peripheral blood T cells were cultured on anti-CD3 plates for 48 hours in the presence or absence of the AT 1 antagonist Losartan (1 μmol/L). Losartan decreased production of TNFα by 30% (Figure 5a) . Surprisingly, the AT 2 antagonist PD123319 also decreased TNFα production by a similar extent, and the combination of these antagonists had an additional effect compared to Losartan alone (Figure 5a ). To avoid non-specific pharmacological effects of Losartan and PD123319, we performed additional experiments using T cells from both AT 1 R -/-and AT 2 R -/-mice (Figure 5b ). Cells from both of these animals produced 60% less TNFα than cells from wild-type C57Bl/6 mice. These findings confirm a role of angiotensin II receptors in modulating T cell production of TNFα.
In additional studies, we found that Losartan had no effect on TNFα production by T cells from AT1R -/-mice and PD123319 had no effect on TNFα production from cells of AT 2 R -/-mice (data not shown), indicating that the effects of these drugs on wild-type cells were unlikely nonspecific.
Role of the NADPH oxidase and reactive oxygen species in modulation of T cell production of TNFα: Angiotensin II potently activates the NADPH oxidase in other cell types, and ROS from this source are known to activate inflammatory signals, in part by activating NFκB-mediated gene transcription. NFκB in turn has been implicated in T cell production of cytokines such as TNFα. We therefore performed additional experiments to determine if endogenouslyproduced angiotensin II could modulate T cell ROS production and if this could impact TNFα production. T cells were exposed to perindopril for 4 hours and superoxide production from these cells was measured using electron spin resonance and the spin probe TMH. T cell production of superoxide was reduced by 30% by perindopril (Figure 6a ). To determine if the NADPH oxidase participates in TNFα production, T cells from p47 phox-/-mice were cultured on anti-CD3 plates for 48 hours and the release of TNFα into the media was measured. Compared to cells from wild-type C57Bl/6 mice, T cells from p47 phox-/-mice produced 40% less TNFα (Figure 6b) .
The above data strongly support a role of angiotensin II in activation of the T cell NADPH oxidase, which then produces ROS to stimulate T cell TNFα production. To gain insight into the specific ROS involved in this process, additional experiments were performed in which T cells were pre-incubated with either PEG-SOD or PEG-catalase (100 U/ml for each) for 4 hours prior to adding cells to anti-CD3 plates. PEG-SOD and PEG-catalase treatment was maintained during exposure to anti-CD3. Control cells were exposed to PEG alone. PEG-SOD decreased T cell production of TNFα by 50% compared to PEG alone, while PEG-catalase was without effect (Figure 6c ). Taken together, these data indicate that superoxide produced by the NADPH oxidase contributes to T cell TNFα production. 
Role of the T cell AT
DISCUSSION
In the present study, we found that T cells produce angiotensin II, which then exerts an autocrine action to stimulate production of superoxide. Superoxide in turn promotes T cell production of the cytokine TNFα. The NADPH oxidase is important in this process, because T cells from p47 phox-/-mice demonstrated reduced production of TNFα. These actions of endogeously produced angiotensin II require T cell receptor ligation with anti-CD3, suggesting that the octapeptide has a role in augmenting ongoing immune responses. Finally, the effects of angiotensin II on T cells seem to be mediated by both AT 1 and AT 2 receptors in that both AT 1 and AT 2 receptor antagonists inhibited T cell production of TNFα and the production of this cytokine was reduced to an equal extent in T cells from mice lacking these receptors. These data are consistent with the scheme presented in Figure 8 .
Our findings are in keeping with prior studies demonstrating that T cells possess components of the renin angiotensin system (24) . The angiotensin-converting enzyme has also been colocalized with T cells in atherosclerotic lesions (7) . Angiotensin II has also been detected in the supernatant of mixed mononuclear cell preparations, although the precise contribution of T cells was not demonstrated (23). To our knowledge, therefore, the current study is the first to definitively document production of angiotensin II by T cells. Of interest, the amount of angiotensin II produced by these cells was substantial, on the order of what we could detect after addition of 100 nM of angiotensin II to the tissue culture. There was also obvious degradation of angiotensin II in the culture, likely by cellular peptidases, because the measured amount of angiotensin II two days following addition of 100 nM (30 pg/ml) was substantially less than the calculated amount that should have been present in the absence of degradation (1 μg/ml). The circulating levels of angiotensin II have been estimated to be approximately 60 pg/ml in humans (22), and to range from 10 to 300 pg/ml in rats based on the level of hydration (26) . Thus, the levels of angiotensin II released in the media of these cells are clearly within a physiological range. Moreover, the media substantially diluted the values we measured such that the intracellular levels of angiotensin II are clearly much higher than the values in the media.
The mRNA levels of the various components of RAS were compared to tissues known to express these proteins. Not surprisingly, T cell expression of the angiotensin I converting enzyme was substantially less than that in the lung, but as much as that in the liver. Likewise, T cells expressed substantially less renin than did the kidney, but more than the liver or lung. In preliminary studies, we found it impossible to maintain T cells in culture without serum and therefore cannot exclude a role of ACE and renin present in T cell production of angiotensin II.
This situation, however, is not unlike that encountered in vivo, where resident T cells in tissue could produce angiotensinogen, which could serve as substrate for renin and subsequently ACE Naïve T cells produce large amounts of TNFα upon activation, at a time when they are migrating to outer T cell zones in lymph nodes (31) . TNFα can down regulate CD4+ cells and modulate the effector phase of CD8+ cells during viral infection (36, 37) . A recent elegant study compared the effects of specific deletion of T cell TNFα using Cre-Lox technology in macrophages and T cells and showed that T cell-derived TNFα plays a critical role in the response to intracellular infectious agents and autoimmune hepatitis (17) . In our previous study, we found that hypertension was associated with a marked infiltration of T cells in the perivascular fat, and that TNFα inhibition with etanercept could prevent the increase in blood pressure and vascular superoxide caused by angiotensin II (18) . It is therefore likely that TNFα production by T cells plays an important role in their function and also modulates adjacent cells.
In the setting of hypertension, these effects of T cell-derived TNFα likely involves stimulation of the vascular NADPH oxidase and superoxide production.
In cell culture, angiotensin II can directly stimulate NADPH oxidase activity in many cell types, including vascular smooth muscle cells and endothelial cells (8, 15) . Our current findings, and those of our previous studies, however indicate that the levels of angiotensin II achieved during chronic infusion are insufficient to directly achieve this effect. It is likely that angiotensin II, TNFα and other cytokines act in concert to amplify the inflammatory process in hypertension. In vascular smooth muscle cells, angiotensin II stimulates TNFα production via activation of the NADPH oxidase and subsequent ROS production, thereby promoting a feed-forward response (40) .
A surprising finding of the present study was that both AT 1 R and AT 2 R receptor blockade reduced T cell production of TNFα. This conclusion was based not only on pharmacological inhibition with Losartan and PD123319, but also on studies of T cells from AT 1 R and AT 2 R deficient mice. In keeping with a role of T cell AT 2 R in increasing blood pressure, we also found that the hypertensive response to angiotensin II was modestly blunted in RAG1 -/-mice after adoptive transfer of AT 2 R -/-T cells. These data are similar to those we previously published showing that the hypertensive response to angiotensin II was blunted following adoptive transfer of AT 1 R -/-T cells compared to that observed following adoptive transfer of wild-type cells (18) . In general, the AT 1 R and AT 2 R have been considered to signal opposite effects, such that the AT 1 R promotes vascular smooth muscle growth, vasoconstriction and superoxide production, while AT 2 R inhibits these events (5) . There are, however, instances in which the AT 2 R has pro-inflammatory roles. As an example, expression of either the AT 1 R or AT 2 R led to similar degress of nuclear factor kappa B (NFκB) activation in COS7 cells (45) . In keeping with this, blockade of both AT 1 R and AT 2 R was required to reduce the inflammation and NFκB activation caused by unilateral ureteral obstruction (10) . In human pre-adipocytes, the angiotensin II-stimulated release of IL-6 and IL-8 is inhibited by AT 1 R blockade and to a lesser extent by AT 2 R inhibition, suggesting that both receptors signal a pro-inflammatory response in these cells (39) . AT 2 R receptors are upregulated in the kidney during angiotensin II infusion at sites of renal inflammation and tubular cell apoptosis, suggesting a role in this pathological response (35) . Our findings that both receptors promote T cell production of TNFα and contribute to hypertension in-vivo are in accord with these prior studies.
Using fluorescent cell sorting, we were unable to demonstrate the presence of AT 2 receptor protein on either the cell surface or intracellularly in T cells despite the above considerations. It is possible that the antibody we employed does not work well for FACS. It is also likely that the AT 2 receptor is present in very low levels that cannot be detected by FACS. In keeping with this, we were only able to detect AT 2 R mRNA using conventional PCR. The fact that PD123319 reduced TNFα production and that T cells from AT 2 R -/-mice produced reduced amounts of TNFα strongly suggests that these cells indeed contain a functioning AT 2 receptor.
This conclusion is further strengthened by our finding that adoptive transfer of AT 2 R -/-T cells in RAG-1 -/-mice led to reduced hypertension compared to adoptive transfer of cells from wild-type
mice.
An interesting finding in our present study is that the majority of T cell AT 1 R receptors are intracellular, and therefore would be particularly prone to activation by endogenously produced angiotensin II. This result is in keeping with the concept that angiotensin II and its receptors can exist as an intracrine system in which signaling occurs within cells (25, 34) . A similar role of intracellular angiotensin II has been demonstrated in the kidney (46), myocardial cells (38) , the central nervous system (12, 21) , and hepatic cells (9) . In the case of myocytes, intracrine angiotensin II has been implicated in hypertrophy (2), and is increased by hyperglycemia (38) . It will be of substantial interest to study factors, such as glucose, that could modulate T cell angiotensin II or its receptors.
It should be emphasized that the pathway outlined in figure 8 only partly explains TNFα and superoxide production by T cells. Blockade of the angiotensin converting enzyme, angiotensin receptors and scavenging of superoxide reduced TNFα production by only about 30 to 60%, indicating that a substantial portion of this is independent of this pathway. Nevertheless, a potentially important portion of T cell TNFα production is linked to this pathway. Given these considerations, our present data support a role of T cell production of angiotensin II in autocrine stimulation of this cell. Further studies are needed to understand the role of T cell endogenously produced angiotensin II in diseases such as these and in cardiovascular pathology.
Perspectives and Significance:
The current study has defined a new pathway in T cells that involves production of angiotensin II, superoxide and the inflammatory cytokine TNFα ( Figure   8 ). We have previously shown that angiotensin II-induced hypertension is associated with accumulation of effector-like T cells in the perivascular fat (18) , and T cells are also known to accumulate in and to promote atherosclerotic lesions (19) . It is therefore likely that this pathway contributes to the progression of vascular disease in these conditions. We believe that T cells are unlikely a major source of superoxide in hypertensive vessels, but that their production of TNFα and other cytokines promotes a pro-oxidant milieu, which together with angiotensin II markedly stimulates the production of reactive oxygen species by adjacent vascular cells. It is also likely that T cell production of angiotensin II, superoxide and TNFα could contribute to inflammation in other settings where T cells accumulate. These findings could explain why interuption of the renin angiotensin system improves T cell mediated diseases such as arthritis (11, 27, 33) , transplant rejection (1), and experimental myocarditis (13) and also provide insight into the recent observation that angiotensin I-converting enzyme inhibition improves endothelial function in humans with rheumatoid arthritis (11) . The fact that both AT 1 and AT 2 receptors contribute to this pathway might also instruct pharmacological therapy and requires further study. In panels B-D mRNA levels in the various cells or tissues is normalized to actin mRNA. 
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